• 4 min read
• Published on 24 October 2025
Listen to article
5:23Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
Let's be honest, the pharmaceutical industry doesn't always get the best press. It’s often painted as a monolithic beast of high prices and even higher profits. Whilst there’s a kernel of truth in that, I think it misses the bigger picture. To me, it’s one of the most fascinating, high-stakes games in the investment world. It’s a place where genuine, life-altering innovation meets brutal, winner-takes-all capitalism. And right now, it seems we’re in the middle of a quiet renaissance, driven by a few standout performers.
Take Sanofi, for instance. For a while, you might have thought of them as a steady, if slightly unexciting, player. Then along came Dupixent. This isn't just another cream for a rash. It’s a precision-engineered treatment for a host of inflammatory conditions, from severe eczema to asthma, and it has completely changed the company’s fortunes. It’s the poster child for what happens when a company gets it spectacularly right. They identified a huge, underserved market and developed a drug that genuinely works wonders. The result? Billions in revenue and a re-energised pipeline. It’s a masterclass in modern pharma strategy, and you can find a more detailed breakdown in the Sanofi Dupixent Success Overview | Pharma Investment if you fancy a deeper dive.
This isn't a one-off story, either. Look at a company like Vertex Pharmaceuticals. They decided to sidestep the crowded markets for common ailments and instead focused on rare genetic diseases like cystic fibrosis. It’s a clever move. By becoming the big fish in a small, desperate pond, they can command premium prices whilst making a profound difference to patients' lives. It’s a strategy that requires immense scientific focus, but the potential rewards are enormous. Then you have the old guard, like Bristol-Myers Squibb, who continue to dominate the fiercely competitive fields of oncology and immunology. They prove that having a portfolio of established blockbusters is a formidable defence against market volatility.
Understanding pharma investing means getting your head around its rather unique economics. Developing a new drug is like drilling for oil in the dark. It’s incredibly expensive, takes a decade or more, and the vast majority of attempts end in costly failure. It’s a brutal game of attrition. But when you strike gold, the gusher can flow for years, protected by a wall of patents. A single successful drug can pay for a hundred failures and then some. This high-risk, high-reward profile isn’t for the faint of heart, of course. It requires a stomach for volatility and an eye for companies that have a knack for backing the right scientific horses. The key, I believe, is spotting firms with not just one promising candidate, but a diversified pipeline of potential winners.
View the full Basket:Sanofi Dupixent Success Overview | Pharma Investment
View the full Basket:Sanofi Dupixent Success Overview | Pharma Investment
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article